Human leukocyte antigen A₂ and psychopathology in chronic schizophrenia

The results suggest that the A₂ patients in the retrospective study might have been less symptomatic before drug treatment and, therefore, gave the impression of making less improvement. This study does not support our original hypothesis that the increased frequency of A₂ in schizophrenic patients was related to poor response to neuroleptics. It suggests, however, that among schizophrenic patients with chronic courses those with A₂ may be less symptomatic. This lends support to the notion that subgrouping schizophrenic patients by biologic characteristics may be valuable.